Yazar "Kumanlioglu, K." seçeneğine göre listele
Listeleniyor 1 - 10 / 10
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The assessment of relation between clinic-pathologic findings and ratios of neutrophil-to-lymphocyte and platelet-to-lymphocyte in papillary thyroid carcinoma(Springer, 2018) Ceylan, Y.; Kumanlioglu, K.; Oral, A.; Ertan, Y.; Ozcan, Z.Öğe Clinical outcome and the value of diagnostic I-131 whole body scintigraphy and recombinant TSH in low-risk well differentiated thyroid cancer patients who have had I-131 radioablation and undetectable thyroglobulin levels(Springer, 2012) Argon, M.; Yararbas, U.; Kumanlioglu, K.; Ozkilic, H.Öğe Comparison of 18F-FDG PET/CT findings with current clinical disease status in patients with Takayasu's arteritis(Clinical & Exper Rheumatology, 2013) Karapolat, I.; Kalfa, M.; Keser, G.; Yalcin, M.; Inal, V.; Kumanlioglu, K.; Pirildar, T.; Aksu, K.Objective. 18F-fluorodeoxyglucosepositron emission tomography/computed tomography (18F-FDG PET/CT) scanning has been proposed as a new tool to assess disease activity in Takayasu arteritis (TA). We investigated whether 18F-FDG PET/CT findings were consistent with current clinical disease status in patients with TA. Methods. In this cross sectional study, 22 patients with TA were enrolled. Clinical disease activity was assessed by the combination of National Institutes of Health (NIH) criteria, Disease Extent Index-Takayasu (DEI-Tak) score, physician global assessment and 18F-FDG PET/CT scans. Results. At the time 18F-FDG PET/CT scans were taken, the majority of the patients (17122) were using immunosuppressive (IS) drugs, and only four patients had clinically active disease. 18F-FDG PET/CT scans confirmed the presence of active vasculitic lesions in those four patients. In 16 out of 18 patients who were accepted to be in clinical remission, 18F-FDG PET/CT scans were also normal. There were only two patients with discordant results, i.e. active 18F-FDG PET/CT findings despite the lack of clinical activity. Interestingly, clinical exacerbation occurred four weeks later in one of them. Overall sensitivity and specificity of 18F-FDG PET/CT findings for clinical activity were 100% and 88.9%, respectively. Conclusion. We found that 18F-FDG PET/CT findings were generally consistent with clinical disease status in TA. Although use of IS drugs certainly impairs diagnostic accuracy of 18F-FDG PET/CT in TA, this imaging method may still have a potential for confirming remission or detecting disease activity in patients with TA receiving treatment.Öğe Comparison of 18F-FDG PET/CT findings with current clinical disease status in patients with Takayasu's arteritis(Clinical & Exper Rheumatology, 2013) Karapolat, I.; Kalfa, M.; Keser, G.; Yalcin, M.; Inal, V.; Kumanlioglu, K.; Pirildar, T.; Aksu, K.Objective. 18F-fluorodeoxyglucosepositron emission tomography/computed tomography (18F-FDG PET/CT) scanning has been proposed as a new tool to assess disease activity in Takayasu arteritis (TA). We investigated whether 18F-FDG PET/CT findings were consistent with current clinical disease status in patients with TA. Methods. In this cross sectional study, 22 patients with TA were enrolled. Clinical disease activity was assessed by the combination of National Institutes of Health (NIH) criteria, Disease Extent Index-Takayasu (DEI-Tak) score, physician global assessment and 18F-FDG PET/CT scans. Results. At the time 18F-FDG PET/CT scans were taken, the majority of the patients (17122) were using immunosuppressive (IS) drugs, and only four patients had clinically active disease. 18F-FDG PET/CT scans confirmed the presence of active vasculitic lesions in those four patients. In 16 out of 18 patients who were accepted to be in clinical remission, 18F-FDG PET/CT scans were also normal. There were only two patients with discordant results, i.e. active 18F-FDG PET/CT findings despite the lack of clinical activity. Interestingly, clinical exacerbation occurred four weeks later in one of them. Overall sensitivity and specificity of 18F-FDG PET/CT findings for clinical activity were 100% and 88.9%, respectively. Conclusion. We found that 18F-FDG PET/CT findings were generally consistent with clinical disease status in TA. Although use of IS drugs certainly impairs diagnostic accuracy of 18F-FDG PET/CT in TA, this imaging method may still have a potential for confirming remission or detecting disease activity in patients with TA receiving treatment.Öğe Demonstrating disease activity in patients with rheumatoid arthritis(Georg Thieme Verlag Kg, 2013) Karapolat, I.; Sertpoyraz, F.; Oncel, G.; Kobak, S.; Yalcin, M.; Kumanlioglu, K.Aim: We aimed to investigate the relationship of fluor-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) with clinical, laboratory pa rameters and conventional radiographs in patients with rheumatoid arthritis (RA). Patients, material, methods: 25 patients with RA diagnosis were evaluated by sociodemo, graphic, clinical [duration of disease (year), the joints in which the complaints started, most recent joint involvement]; other parameters used in RA-specific clinical assessment [Steinbocker functional staging, disease activity score 28 (DAS 28 score), health assess, ment questionnaire score (HAQ score), general RA assessment (patients' and physicians' global assessment), patients' assessments of "pain and general health condition (visual analog scale)], laboratory, radiological [conventional radiology of hand and foot joints], positron emission tomography [F-18 FDG PET visual total score and maximum standardized uptake value (SUVmax) total score] parameters. Results: No significant correlation was detected between the F-18 FDG PET total score and SUVmax total score of the patients and clinical, laboratory, and radiological parameters (p > 0.05). There was no relationship between the cut-off values determined according to the disease activity and F-18 FDG PET/SUVmax total values (p > 0.05). Conclusions: In our study, no relationship was found between disease activity demonstrated by F-18 FDG PET/CT in RA patients and clinical, laboratory, and radiological parameters. F-18 FDG PET/CT appears to be a more sensitive method in demonstrating disease activity compared to other evaluated methods.Öğe Demonstrating disease activity in patients with rheumatoid arthritis(Georg Thieme Verlag Kg, 2013) Karapolat, I.; Sertpoyraz, F.; Oncel, G.; Kobak, S.; Yalcin, M.; Kumanlioglu, K.Aim: We aimed to investigate the relationship of fluor-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) with clinical, laboratory pa rameters and conventional radiographs in patients with rheumatoid arthritis (RA). Patients, material, methods: 25 patients with RA diagnosis were evaluated by sociodemo, graphic, clinical [duration of disease (year), the joints in which the complaints started, most recent joint involvement]; other parameters used in RA-specific clinical assessment [Steinbocker functional staging, disease activity score 28 (DAS 28 score), health assess, ment questionnaire score (HAQ score), general RA assessment (patients' and physicians' global assessment), patients' assessments of "pain and general health condition (visual analog scale)], laboratory, radiological [conventional radiology of hand and foot joints], positron emission tomography [F-18 FDG PET visual total score and maximum standardized uptake value (SUVmax) total score] parameters. Results: No significant correlation was detected between the F-18 FDG PET total score and SUVmax total score of the patients and clinical, laboratory, and radiological parameters (p > 0.05). There was no relationship between the cut-off values determined according to the disease activity and F-18 FDG PET/SUVmax total values (p > 0.05). Conclusions: In our study, no relationship was found between disease activity demonstrated by F-18 FDG PET/CT in RA patients and clinical, laboratory, and radiological parameters. F-18 FDG PET/CT appears to be a more sensitive method in demonstrating disease activity compared to other evaluated methods.Öğe THE EFFECTS OF RALOXIFENE ON OSTEOCALCIN, AS A BONE TURNOVER MARKER IN ORCHIECTOMIZED RATS(Editura Acad Romane, 2014) Saklamaz, A.; Uyulgan, B.; Sevin, G.; Kebapcilar, L.; Yilmaz, O.; Cimrin, D.; Kumanlioglu, K.; Bayraktar, F.Background. The aim of the present study was to measure the effects of raloxifene on bone metabolism and strength in orchiectomized male rats. Materials/Methods. Forty-three 4-month-old Wistar albino male rats were used and divided into 3 groups as orchiectomy (ORCX; n=23), sham (n=15), and control (n=5). Raloxifene (10 mg/kg/day) and methylcellulose (0.5 mL/day, as a vehicle treatment) treatments were initiated 2 months after ORCX for 2 months, then the rats were sacrificed. The left femur and fourth lumbar vertebrae (LV4) were measured to assess the effects of the orchiectomy and the raloxifene treatment and maintenance regimens. Bone strength was assessed using a compression test for the vertebrae and a three-point bending test for the femurs (N/mm). Results. Raloxifene increased femoral and vertebral bone strength in osteoporotic rats, but this increase was not statistically significant. Bone strength was found to be 267.44 +/- 18.03 in the femurs of the ORCX-raloxifene group and 246.32 +/- 49.37 in the femurs of the ORCX-C group (p>0.05). Vertebral bone strength was 147.78 +/- 09.51 in the ORCX-raloxifene group and 114.61 +/- 05.93 in ORCX-C group (p=0.488). Raloxifene also increased the femoral and vertebral bone density compared with the control group, but the change was not significant. While raloxifene significantly decreased the serum osteocalcin levels (p=0.007), it did not decrease the carboxyterminal cross-linking telopeptide of bone collagen (CTX) levels significantly (p=0.066). Conclusions. Raloxifene caused a statistically significant decrease in serum osteocalcin levels and a non-significant reduction in NTX levels in orchiectomized rats.Öğe Evaluation Of F-18 FDG PET/CT In Differentiated Thyroid Cancers(Springer, 2018) Yazici, B.; Alcicek, S.; Oral, A.; Akgun, A.; Kumanlioglu, K.Öğe Evaluation of F-18 FDG PET/CT in Differentiated Thyroid Cancers(Springer, 2018) Yazici, B.; Alcicek, S.; Oral, A.; Akgun, A.; Kumanlioglu, K.[No Abstract Available]Öğe IMPACT of 131-I SPECT/CT in STAGING or FOLLOW-UP of DIFFERENTIATED THYROID CARCINOMA(Springer, 2013) Omur, O.; Oral, A.; Tugral, B.; Tekin, E.; Kumanlioglu, K.
